Amalya Sargsyan

Amalya Sargsyan: Novel weapons in LCSM to be presented at ASCO

Amalya Sargsyan, Medical Oncologist at the Yeolyan Oncology and Hematology Center, shared a post on X:

“Novel weapons in LCSM to be presented at ASCO.

Sunvozertinib in EGFR exon20 NSCLC with 61%ORR and 88%DCR

Zongertinib for HER2 mutant NSCLC with 45%ORR & 91%DCR

Taletrecrinib in ROS1+ NSCLC, ORR 92% & DCR of 89.5%

SGNB6A-001 for advanced solid tumors 33%ORR in NSCLC”

Source: Amalya Sargsyan/X
OncoDaily

Advanced solid tumors ASCO cancer Disease control rate EGFR exon20 NSCLC HER2 mutant NSCLC LCSM Lung cancer novel therapies objective response rate OncoDaily Oncology ROS1+ NSCLC SGNB6A-001 Sunvozertinib Taletrecrinib Talha Badar treatment outcomes Zongertinib